Newsroom | 53457 results

OKLAHOMA CITY--(BUSINESS WIRE)--Cytovance Biologics, a leading US-based contract development and manufacturing organization (CDMO) serving the biopharmaceutical industry, today announced the expansion of its analytical services portfolio with standalone analytical capabilities for biotechnology and pharmaceutical clients. The new approach provides access to Cytovance's experienced analytical team and regulatory-ready analytical solutions without requiring a manufacturing engagement. Building on...

CHAPEL HILL, N.C.--(BUSINESS WIRE)--UNC Health Launches UNC Health Ventures...

SAN FRANCISCO & NEW YORK--(BUSINESS WIRE)--Longevica names former Genentech/Roche executive Dr. Prasun Mishra CEO to advance its $13M mammalian longevity study toward IND-enabling development....

BOULDER, Colo.--(BUSINESS WIRE)--1 in 8 US adults are reported to use GLP-1 medications, but the majority of people who primarily take them for weight loss stop using them within one year of starting [1,2]. A recent meta-analysis by the University of Oxford estimated that any benefits on body weight and other metabolic health markers, such as HbA1c, are lost in the majority of people who stop GLP-1 medications, and that weight regain post-GLP-1 is faster than after non-drug weight management pr...

ISELIN, N.J--(BUSINESS WIRE)--Ephicacy today announced the appointment of Dr. Shekhar Thumake as head of AI, a new role that reflects the company’s growing investment in artificial intelligence across its biometrics operations. In this role, Thumake will lead Ephicacy’s enterprise AI strategy and the development of agentic AI capabilities designed to connect and streamline clinical data workflows. He will collaborate closely with clients and delivery teams to identify high-value applications of...

SAN DIEGO--(BUSINESS WIRE)--858 Therapeutics, a clinical-stage biotechnology company, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to ETX-19477, the company’s internally discovered PARG inhibitor. The designation has been granted for the treatment of adult patients with BRCA-mutated, hormone receptor positive (“HR+”), human epidermal growth factor receptor 2 negative (“HER2-”), unresectable or metastatic breast cancer. “For patients with ad...

STUART, Fla.--(BUSINESS WIRE)--Stuart Therapeutics, Inc. (“Stuart”), a clinical-stage biopharmaceutical company developing first-in-class collagen-reparative therapeutics to treat eye diseases, today announced the appointment of David Jakeman as chief financial officer. Jakeman will lead the company's finance and accounting operations as Stuart advances its lead candidate, ST-100 for dry eye disease, through completion of its pending Phase 3b clinical trial and into preparations for commerciali...

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Brixton Biosciences (Brixton), a clinical-stage life sciences company focused on developing a nerve-selective biomaterial designed to provide targeted and durable relief from pain, today announced the appointment of three new members to its Board of Directors: founding CEO of Alnylam Pharmaceuticals and RNAi pioneer, John Maraganore, Ph.D.; CEO of Bausch + Lomb and biopharma deal-maker, Brent Saunders; and former General Manager, Philadelphia 76ers, Elton Bran...

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Amylyx Pharmaceuticals, Inc. (Nasdaq: AMLX) (“Amylyx” or the “Company”) today announced positive topline results from LUCIDITY, a 78-participant, multicenter, randomized, double-blind, placebo-controlled Phase 3 clinical trial evaluating the efficacy and safety of avexitide, an investigational, first-in-class glucagon-like peptide-1 (GLP-1) receptor antagonist, in participants with post-bariatric hypoglycemia (PBH) following Roux-en-Y gastric bypass (RYGB) sur...

NEWTON, Mass.--(BUSINESS WIRE)--Abcuro, Inc., a clinical-stage biotechnology company developing therapies for the treatment of autoimmune diseases through precise modulation of cytotoxic T cells, today announced the closing of a $66 million Series D financing led by current investor New Leaf Venture Partners with participation of existing investors including funds managed by abrdn Inc., Bain Capital Life Sciences, Samsara BioCapital, Redmile Group, Mass General Brigham Ventures, RA Capital Mana...